SIMULATIONS PLUS INC

Company Overview

Simulations Plus, Inc. (SLP) develops simulation and modeling software and related services for the pharmaceutical/biotech market (PBPK, QSP and related modeling), and has grown inorganically through recent acquisitions such as Pro‑ficiency. Q3 FY2025 revenue was $20.4M (up 10% year-over-year; YTD +20%), but gross margin compressed (71% → 64% in the quarter; YTD 71% → 59%) and the company reported a large noncash impairment ($77.2M) that produced a Q3 net loss. Management cites acquisition-related amortization, higher service delivery costs and a mixed demand environment across service lines as drivers; liquidity remains positive with ~$27M cash and $41.6M net working capital and a $30M repurchase authorization that was unused this period. Key operational risks are integration execution, utilization and project mix volatility, and sensitivity of valuation to revenue underperformance.

Executive Compensation Practices

Given SLP’s mix of perpetual software licenses, services and acquisitions, executive pay is likely tied to revenue growth (including revenue from acquisitions), recurring/license sales, gross margin and successful integration milestones rather than just short‑term EPS. The sizable impairment and acquisition amortization implications mean equity-based pay (stock options, PSUs) and long‑term incentive plans will be volatile in value and may be structured to focus on cash‑flow, deferred revenue conversion, or deal integration targets to better align pay with sustainable performance. Acquisition earnouts and contingent considerations (e.g., Immunetrics settlement) suggest compensation/bonus plans may include deal-related milestones and retention awards for key acquired management. Boards in this industry often add retention bonuses and time‑vested equity following acquisitions; they may also include clawback or repricing provisions to address material write‑downs and accounting adjustments.

Insider Trading Considerations

Insider trading activity at SLP is likely sensitive to acquisition news, integration progress, quarterly invoicing/seasonality and the large impairment event that materially altered reported earnings — all of which can drive share volatility and timing of executive trades. Expect tighter trading windows and use of 10b5‑1 plans around acquisitions and quarterly results; executives may buy shares to signal confidence given solid operating cash flow, or sell for tax/liquidity reasons after one‑time impairments reduce share prices. Regulatory and contractual constraints (SEC reporting, confidentiality with pharma clients, and potential data‑handling/compliance obligations tied to customer contracts) increase the likelihood of blackout periods and preclearance policies. Finally, the unused repurchase authorization and potential future financing for M&A are additional signals that insiders may use when deciding to transact or publicly communicate share purchases.